Abstract:Background: Gastrointestinal symptoms are common in Coronavirus Disease 2019 (COVID-19), related to infection of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) of intestinal cells through the angiotensin converting enzyme 2 (ACE2) receptor in the brush border. Also, patients are treated with multiple antibiotics. Therefore, an increase in gut dysbiosis and in the prevalence of Clostridium difficile infection (CDI) is expected in patients with COVID-19. Methods: A PubMed search was conducted using the terms "gut microbiota," "gut mycobiota," "dysbiosis" AND "COVID-19"; "Clostridium difficile," "Clostridioides difficile" AND "COVID-19"; "probiotics," "bacteriotherapy AND COVID-19." Only case series, observational and experimental studies were included. Results: A total of 384 papers were retrieved and 21 fulfilled selection criteria. Later, a new paper was identified, thus 22 papers were reviewed. Main findings: (1) gut bacterial dysbiosis has been found in fecal samples of COVID-19 patients, with enrichment of opportunistic organisms and decrease of beneficial commensals such as Faecalibacterium prausnitizii. Dysbiosis is related to inflammatory markers and illness severity. (2) There is evidence for abnormal gut barrier and bacterial translocation with a negative impact in the lungs. (3) Fungal dysbiosis correlating with pulmonary mycobiota, has also been found. (4) There is controversy in the CDI rates among COVID-19 patients versus controls and pandemic versus prepandemic era. (5) There is no available evidence yet to support bacteriotherapy in COVID-19. (6) Fecal microbiota transplantation (FMT) has been proposed for COVID-19, although there is no evidence to support it. Also, FMT can be safely used during the pandemic for CDI if strict screening protocols for donors and fecal product are implemented. Conclusions: In COVID-19 there is bacterial and fungal dysbiosis that correlates with systemic and pulmonary inflammation, and illness severity. Further investigations are warranted to determine the efficacy of bacteriotherapy and FMT for modulating gut dysbiosis in COVID-19.

Candida in COVID-19: Gut-Lung Axis, Dysbiosis, and Infections

Gut-lung axis and dysbiosis in COVID-19

Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review

Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.

Microbiota Modulation of the Gut-Lung Axis in COVID-19

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

The lung-gut axis and COVID-19

Gut-Lung Axis-A Compass to Navigate Microbiome Landscape in COVID-19

Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Gut mycobiota alterations in patients with COVID-19 and H1N1 and associations with immune and gastrointestinal symptoms

Overview of COVID-19-Associated Invasive Fungal Infection

Gut Microbiome and COVID 19 Role of Probiotics on Gut Lung Axis

Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity

Candida auris and COVID-19: A health threatening combination

Gut microbiota and COVID‐19: A systematic review

COVID-19 and Gut Microbiota: A Potential Connection

The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections

Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

COVID-19 and the Human Gut Microbiome: An Under-Recognized Association